Literature DB >> 17143812

Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy.

Brigitte Ranque1, Van Thuc Nguyen, Hong Thai Vu, Thu Huong Nguyen, Ngoc Ba Nguyen, Xuan Khoa Pham, Erwin Schurr, Laurent Abel, Alexandre Alcaïs.   

Abstract

BACKGROUND: Reversal, or type 1, leprosy reactions (T1Rs) are acute immune episodes that occur in skin and/or nerves and are the leading cause of neurological impairment in patients with leprosy. T1Rs occur mainly in patients with borderline or multibacillary leprosy, but little is known about additional risk factors.
METHODS: We enrolled 337 Vietnamese patients with leprosy in our study, including 169 subjects who presented with T1Rs and 168 subjects with no history of T1Rs. A multivariate analysis was used to determine risk factors for T1R occurrence, time to T1R onset after leprosy diagnosis, and T1R sequelae after treatment.
RESULTS: Prevalence of T1Rs was estimated to be 29.1%. Multivariate analysis identified 3 clinical features of leprosy associated with T1R occurrence. Borderline leprosy subtype (odds ratio, 6.3 [95% confidence interval, 2.9-13.7] vs. polar subtypes) was the major risk factor; 2 other risk factors were positive bacillary index and presence of > 5 skin lesions. In addition, age at leprosy diagnosis was a strong independent risk factor for T1Rs (odds ratio, 2.4 [95% confidence interval, 1.3-4.4] for patients aged > or = 15 years old vs. < 15 years old). We observed that T1Rs with neuritis occurred significantly earlier than pure skin-related T1Rs. Sequelae were present in 45.1% of patients who experienced T1Rs after treatment. The presence of a motor or sensory deficit at T1R onset was an independent risk factor for sequelae, as was the age at diagnosis of leprosy (odds ratio, 4.4 [95% confidence interval, 1.7-11.6] for patients > or = 20 years old vs. < 20 years old).
CONCLUSION: In addition to specific clinical features of leprosy, age is an important risk factor for both T1R occurrence and sequelae after treatment for T1Rs.

Entities:  

Mesh:

Year:  2006        PMID: 17143812     DOI: 10.1086/509923

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

1.  Transcriptional changes that characterize the immune reactions of leprosy.

Authors:  Kathryn M Dupnik; Thomas B Bair; Andressa O Maia; Francianne M Amorim; Marcos R Costa; Tatjana S L Keesen; Joanna G Valverde; Maria do Carmo A P Queiroz; Lúcio L Medeiros; Nelly L de Lucena; Mary E Wilson; Mauricio L Nobre; Warren D Johnson; Selma M B Jeronimo
Journal:  J Infect Dis       Date:  2014-11-14       Impact factor: 5.226

2.  Field-Friendly Test for Monitoring Multiple Immune Response Markers during Onset and Treatment of Exacerbated Immunity in Leprosy.

Authors:  Paul L A M Corstjens; Anouk van Hooij; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Louis Wilson; Annemieke Geluk
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

3.  Association of TNF, MBL, and VDR polymorphisms with leprosy phenotypes.

Authors:  Bishwa R Sapkota; Murdo Macdonald; William R Berrington; E Ann Misch; Chaman Ranjit; M Ruby Siddiqui; Gilla Kaplan; Thomas R Hawn
Journal:  Hum Immunol       Date:  2010-08-01       Impact factor: 2.850

Review 4.  Leprosy and the human genome.

Authors:  Elizabeth A Misch; William R Berrington; James C Vary; Thomas R Hawn
Journal:  Microbiol Mol Biol Rev       Date:  2010-12       Impact factor: 11.056

5.  Risk factors for leprosy reactions in three endemic countries.

Authors:  David M Scollard; Celina M T Martelli; Mariane M A Stefani; Maria de Fatima Maroja; Laarni Villahermosa; Fe Pardillo; Krishna B Tamang
Journal:  Am J Trop Med Hyg       Date:  2014-12-01       Impact factor: 2.345

6.  The Burden of Helminth Coinfections and Micronutrient Deficiencies in Patients with and without Leprosy Reactions: A Pilot Study in Minas Gerais, Brazil.

Authors:  Jessica K Fairley; Jose A Ferreira; Ana Laura Grossi de Oliveira; Thelma de Filippis; Maria Aparecida de Faria Grossi; Laura Pinheiro Chaves; Luiza Navarro Caldeira; Paola Souza Dos Santos; Rafaella Rodrigues Costa; Maria Cavallieri Diniz; Carolina Soares Duarte; Luiz Alberto Bomjardim Pôrto; Parminder S Suchdev; Deborah Aparecida Negrão-Corrêa; Fernanda do Carmo Magalhães; João Marcelo Peixoto Moreira; Adelino de Melo Freire Júnior; Mariana Costa Cerqueira; Uriel Kitron; Sandra Lyon
Journal:  Am J Trop Med Hyg       Date:  2019-11       Impact factor: 2.345

7.  Paradoxical reactions during treatment of tuberculosis with extrapulmonary manifestations in HIV-negative patients.

Authors:  G Geri; A Passeron; B Heym; J-B Arlet; J Pouchot; L Capron; B Ranque
Journal:  Infection       Date:  2012-12-01       Impact factor: 3.553

8.  A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment.

Authors:  Stephen L Walker; Peter G Nicholls; Sushmita Dhakal; Rachel A Hawksworth; Murdo Macdonald; Kishori Mahat; Shudan Ruchal; Sushma Hamal; Deanna A Hagge; Kapil D Neupane; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2011-04-12

9.  Human polymorphisms as clinical predictors in leprosy.

Authors:  Ernesto Prado Montes de Oca
Journal:  J Trop Med       Date:  2011-12-18

10.  Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy.

Authors:  Luciana Silva Rodrigues; Mariana Andrea Hacker; Ximena Illarramendi; Maria Fernanda Miguens Castelar Pinheiro; José Augusto da Costa Nery; Euzenir Nunes Sarno; Maria Cristina Vidal Pessolani
Journal:  BMC Infect Dis       Date:  2011-12-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.